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ents. Symptomsof gastroenteritis, includingvomitinganddiarrhea,
occurring in the in-patient unit were recorded post-challenge.
Results: In the per protocol population, 4/48 (8.3%) of placebo
subjects and0/50 (0%)of vaccine subjects experienced severevomi-
ting (100% reduction, p =0.054). 8/48 placebo subjects (16.7%) vs. 1
vaccine subject (2.0%) experienced moderate or severe vomiting
(88.0% reduction, p =0.015), and 17/50 placebo subjects (35.4%)
vs. 4/48 vaccine subjects (8.0%) experienced mild, moderate or
severe vomiting (77.4% reduction, p =0.001). Reports of vomiting
or diarrhea of any severity were signiﬁcantly reduced in the vac-
cine group (10/50, 20%) compared with the placebo group (20/48,
41.7%; p=0.028), a 52% reduction.
Conclusion: In this study the experimental norovirus vaccine
was associated with signiﬁcant reductions in vomiting. This biva-
lent norovirus vaccinemayprovide ameans to reduce transmission
via aerosolized virus and contaminated fomites as a result of a
reduction in vomiting episodes. Field efﬁcacy studies arewarranted
to further evaluate protection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1316
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Background: In 2010, a conjugate meningococcal serogroup A
(NmA) vaccine (PsA-TT; MenAfriVacTM) was introduced in Africa’s
ﬁrst-everpreventativemeningococcalmass-vaccinationcampaign.
PsA-TT clinical trials indicate that immunity against serogroup A
disease persists for at least one year and that vaccination boosts
tetanus immunity because tetanus toxoid is used as a carrier pro-
tein. Yet, questions remain about long-term antibody persistence
againstmeningococcal serogroupAand theextentof tetanusboost-
ing in the population following introduction.
Methods & Materials: We conducted a cross-sectional
household-based age-stratiﬁed seroprevalence survey in Banconi,
Bamako, Mali in 2012. Randomly selected participants (n =800)
were eligible if they were present in Bamako and aged 1-29 years
during the 2010 vaccination campaign and if they were healthy
at enrollment. Serum samples were analyzed to determine NmA-
speciﬁc serum bactericidal antibody (rSBA) titers (reference strain
F8238), NmA-speciﬁc total IgG using enzyme-linked immunosor-
bent assay (ELISA), and anti-tetanus toxoid IgG concentrations by
ﬂorescent bead assay. The relationship between several predictive
factors and immunitywasalso assessed. Labandquestionnairedata
were analyzed with STATA v12.1.
Results: All participants were living in Bamako and eligible
to receive PsA-TT during the mass-vaccination campaign; 99.5%
reported receiving the vaccine. Nearly all participants (99.0%) had
NmA-speciﬁc SBA titers ≥8, the standard protective threshold;
97.8% had SBA titers ≥128; 89.5% had SBA titers ≥1024. SBA geo-
metric mean titers were higher in females than males except in
participants >18 years of age at vaccination. IgG levels ≥2g/mL
were found in 88.5% of participants. Forty two percent of partici-
pants had anti-tetanus IgG levels less than 1.0 IU/mL, indicating a
lack of long-term protection against tetanus. Twelve percent had
anti-tetanus IgG levels less than 0.1 IU/mL, indicating no evidence
of tetanus immunity (Fig. 1).
Fig. 1 Distribution of anti-tetanus lgG tetors by age and sex
based on age at enrollment in December 2012, Two years after
the PaA-IT mass vaccination campaign.
Conclusion: Two years after the PsA-TT mass-vaccination cam-
paign, we found evidence of persistent immunity against NmA in
Mali. However, there is a lack of evidence that PsA-TT has boosted
tetanus immunity, which may be explained by limited exposure
to primary tetanus vaccination in this population prior to PsA-TT
introduction. Our study highlights the need to go beyond clinical
trials and assess long-term vaccine effectiveness post-introduction
in representative populations.
http://dx.doi.org/10.1016/j.ijid.2014.03.1317
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Background: Lactococcus lactis, a generally recognized as safe
(GRAS) bacterium, has become a growing interest in vaccine
research due to its non-pathogenic and non-colonizing proper-
ties. It is an attractive tool to deliver antigens by mucosal routes,
which could eventually elicit protective immunity, both systemic
and mucosal immunity. Considering inﬂuenza virus is a mucosal
pathogen, gaining entry into humans via the mucosal surface, an
ideal inﬂuenza vaccine that is able to generate both systemic and
mucosal immunity is required. The present study aims to develop a
candidate vaccine for inﬂuenza using L. lactis as a vehicle to deliver
inﬂuenza antigens.
Methods & Materials: In this study, we constructed a recombi-
nant plasmid consisting of genes encoding the truncated inﬂuenza
A virus antigenic protein, hemagglutinin (HA1), and the cell wall
bindingdomainprotein,N–acetylmuraminidase (AcmA),which are
linked together by a single-chain variable fragment (scFv) linker.
The recombinant plasmidwas transformed into Escherichia coli and
the expression of the HA1 fusion protein was induced using iso-
propyl -D thiogalactosidase (IPTG). The inclusion bodies formed
were puriﬁed under denaturing condition by afﬁnity chromatog-
raphy and refolded by dialysis. The resulting functionally active
fusion protein was surface displayed on the L. lactis. Optimizations
were performed to improve the binding capacity of the HA1 fusion
protein onto the surface of the L. lactis. This construct, the L. lactis
surface displaying HA1 fusion protein, was then administered into
436 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
mice to evaluate the host immune responses towards the fusion
protein.
Results: A functionally active HA1 fusion protein consisting of
theHA1andAcmAprotein, linked together by a scFv linkerwas suc-
cessfully expressed andpuriﬁed. The fusionprotein has amolecular
mass of approximately 50kDa. Examination of the conditions for
binding of the fusion protein to L. lactis showed that a mixture of
20g of fusion protein with 108-109 L. lactis cells, GM17 as buffer
for binding and a binding incubation period of 2hours are most
suitable.
Conclusion: L. lactis surface displayingHA1 fusionprotein could
potentially develop as an alternative oral vaccine for preventing
inﬂuenza virus infection in humans.
http://dx.doi.org/10.1016/j.ijid.2014.03.1318
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HLA class II association with visceral
leishmaniasis: The road to identifying vaccine
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Background: Leishmaniasis, aneglected tropical disease, preva-
lent in developing countries with 90% of them in Asia (Bangladesh,
India, and Nepal), Sudan, Ethiopia and Brazil. The technical chal-
lenges and the complexity in the immunity against the parasites
clearly contribute to the absence of vaccines. A major challenge in
humanvaccinedesign is toovercomevariation in immuneresponse
in a genetically heterogeneous population. This is largely deter-
mined by genetic heterogeneity in processing and presentation of
Ag to T cells, the outcome of which is dependent on binding of T
cell epitopes toHLA class I and class IImolecules that drive CD8 and
CD4T cell responses, respectively.
In silico screening for putative epitopes binding to DRB1
molecules can identify multiple epitopes per single parasite anti-
gen. Our quest here is to determinewhat actually occurs during the
course of a complex infection in vivo.
Methods & Materials: We are using in silico prediction tools
in an effort to understand more about the processes that direct
antigen selection and binding to different DRB1 molecules dur-
ing natural leishmanial infection. This will be done in concert with
analysis of naturally processed leishmanial peptides. A previously
conducted GWAS and further sequence based haplotyping on an
Indian population has indicated HLA class II as a major genetic risk
factor for visceral leishmaniasis(VL) and revealed DRB1*13/14 and
DRB1*15/16 as risk and protective alleles, respectively in VL. In a
preliminary study, we have obtained data on leishmanial epitopes
predicted to bind to DRB1*13/*14 risk vs DRB1*15/*16 protective
class II molecules using the in-silico predictive tool NetMHCIIpan
v2.1.
Results: Data for overlapping 9-mer epitopes has been gen-
erated for 27 known Leishmania antigens (antigens of diagnostic
value, vaccine candidates) and we have found peptides exclusively
binding to risk as well as protective group and also some differen-
tially binding peptides.
Conclusion: Functional validationof thesepeptideswill bedone
by measuring immune response against these antigens in individ-
uals carrying different allele group from endemic region in India.
Thiswill pave theway for appropriatevaccinecandidateswhichcan
drive the immune response to protective response in genetically
susceptible individuals.
http://dx.doi.org/10.1016/j.ijid.2014.03.1319
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Australian zoster study: GP and patient views
about herpes zoster (shingles), its
complications, and the likely acceptance of a
zoster vaccine (Zostavax)
J.C.B. Litt1,∗, S. Kim1, R. Woodman1, R.
MacIntyre2, T. Cunningham3
1 Flinders University„ Adelaide, Australia
2 University of New South Wales, Sydney, Australia
3 The University of Sydney, Sydney, Australia
Background: Shingles causes considerable morbidity in older
persons. Zostavax, a vaccine against shingles, reduces the incidence
of shingles by 50% and the burden of illness by two-thirds. Little is
known about the factors that contribute to the patient’s intention
to get Zostavax
Methods & Materials: A two stage simple random sampling
process was undertaken to identify a random sample of GPs across
two urban areas in South Australia to identify the key beliefs about
shingles and its complications and the factors that may inﬂuence
the uptake of the Zostavax.
A random sample of each selected GP’s patients aged between
60 and 85 who had visited that GP at least once in the last 2 years
was selected and in interviewed by phone.
Principal component factor analysis with orthogonal (varimax)
rotation was used to reduce the number of patient characteristics
associated with vaccination intention in bivariate comparisons.
Survey weighted responses from GPs and patients were exam-
ined for their association with the patients’ likelihood to receive
the vaccine using the logistic regression
Results: Fifty GPs and 1330 patients were interviewed. About
half the GPs were very likely to recommend the Zoster vaccine.
82% of the patients knew of someone who had had shingles and
50% believed that it would have a big impact on their life. Just over
half would get Zostavax and 89% would, if their GP recommended
it.
The main predictor of getting Zostavax was if the patient’s GP
recommended it (OR 21.6 95% CI 13.8- 33.8). In factor analysis,
58 patient characteristics were reduced to 16 patient factors that
explained 73% of variance in patient intention to get Zostavax. After
adjustment for other predictors, GP recommendation remained the
strongest predictor of patient intention to get the Zoster vaccine.
